A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Taofeek K OwonikokoRobert Donald HarveyBradley CarthonZhengjia ChenColleen LewisHanna CollinsChao ZhangDavid H LawsonOlatunji B AleseMehmet Asim BilenGabriel L SicaConor E SteuerWalid L ShaibChristina WuWayne B HarrisMehmet AkceRagini R KudchagkarBassel F El-RayesSagar LonialSuresh S RamalingamFadlo Raja KhuriPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The combination of everolimus and buparlisib is safe and well-tolerated at the RP2D of 5 and 60 mg on a continuous daily schedule.